Newsroom

May 27, 2026

Myriad Genetics AI-Enhanced Prostate Cancer Test Aims to Improve Active Surveillance Decisions

Read more
June 18, 2026

Jackie Tohn Credits Genetic Testing With Saving Her Life

Read more
July 21, 2026

Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen

Read more
July 9, 2026

Myriad Genetics Expands Indications, Broadens Commercial Strategy for Ultrasensitive MRD Test

Read more
May 12, 2026

The World's Most Impactful Companies of 2026

Read more
August 4, 2026

Forbes America's Best Employers for Women 2026 List

Read more
previous slide
    next slide

    Scientific publications

    See all

    Key study finding: ctDNA levels detected using Precise MRD were associated with patients’ response to metastasis-directed radiation therapy

    DOI: 10.1016/S1470-2045(25)00380-8
    Publication Press release

    Meta-Analysis demonstrates that Access to the GeneSight test can significantly improve response and remission rates for patients with depression

    DOI: 10.1097/JCP.0000000000002061
    Publication Press release

    Study suggest that utilizing RiskScore drives breast cancer screening tailored to individual risk

    DOI: 10.1200/PO-24-00716
    Publication Press release

    Study results show patients with depression had fewer psychiatric hospitalizations after GeneSight testing

    DOI: 10.1097/JCP.0000000000001999
    Publication Press release

    Prolaris can predict the benefit of hormone therapy treatment in localized prostate cancer

    DOI: 10.1200/PO.23.00722
    Publication Press release
    previous slide
      next slide

      Press releases

      See all

      Oct 22, 2026

      Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

      Read more

      Oct 20, 2026

      Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

      Read more

      Oct 15, 2026

      Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026

      Read more

      Oct 08, 2026

      Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

      Read more

      Public relations contacts

      Kate Schraml

      pr@myriad.com

      Investor relations contacts

      Matt Scalo

      ir@myriad.com
      X social media icon Linkedin social media icon

      About Myriad Genetics

      Myriad Genetics is a leader in genetic testing and precision medicine, providing insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease. 

      • Early insights helped Ashley prepare

        “Carrier screening empowers you to make the right decisions. Not only are you making a decision for yourself right now but you’re making a decision for the next 80, 90, 100 years to create a better life for you and your baby.”
        Watch Ashley's story

      • Prenatal screening gave Hannah time to plan

        “Once we got the noninvasive prenatal screening results back, we were able to meet with a lot more physicians.”

      • How Prolaris provided clarity for his prostate cancer treatment plan

        “Prolaris gave me the ability to maintain the lifestyle that my wife and I have lived with for many years now.”
        Watch Tim's story
      previous slide
        next slide